EMJ Podcast: Insights For Healthcare Professionals

In the final episode of this series, Dr Carl Streed Jr explores the evolving evidence base, risk assessment, and policy landscape in transgender healthcare. From cardiovascular outcomes and research challenges to the interpretation of emerging evidence in healthcare and sport, this episode examines how clinicians, researchers, and policymakers can translate evidence into guidance while advancing inclusive, equitable care.

Timestamps:

01:00 – Cardiovascular Risk in Transgender Patients

04:29 – Sports Governing Bodies

06:05 – Methodological Challenges

07:26 – Translating Evidence into Guidance

How can clinical practice evolve to deliver more inclusive gender-affirming care? In Part 2, Carl Streed Jr shares insights from his research on implementing equitable healthcare, including the impact of targeted education, barriers to care delivery, and the role of training programmes in building long-term clinical competence. A must-listen for clinicians seeking to understand the evidence, practice, and future of transgender healthcare.

Timestamps:

01:08 – Providing Training on Gender Affirming Care

02:32 – Barriers to Gender Affirming Care

03:29 – Well-Rounded Gender-Affirming Care

04:45 – When to Look at Sex, and When to Look at Affirmed Gender?

06:27 – Focusing on the Person and the Medicine

08:11 – Continuity of Care

10:20 – Advocacy

Carl Streed Jr joins host Catherine Glass to explore how healthcare systems can advance equity and inclusion for sexual and gender minority populations. From improving continuity of care and electronic health record design to addressing structural disparities and embedding equity at a systems level, this episode examines how research and implementation can transform LGBTQIA+ healthcare.

Timestamps:

01:02 – Continuity of Care

02:06 – Reshaping Electronic Health Records

04:08 – Equity at a Systems Level

In this rapid-fire episode, Carl Streed Jr answers key questions about transgender healthcare and LGBTQIA+ health equity, from the biggest barriers and research priorities to clinical training, inclusive practice, and the future of gender-affirming care. Perfect for listeners looking for concise insights into the challenges and opportunities shaping equitable healthcare.

This episode was funded by Stemline Therapeutics, Inc., a Menarini Company Group, and is intended for United States healthcare professionals only.

The opinions expressed here are solely those of the named speaker and do not represent those of his affiliated institution. His participation in this discussion does not constitute, and should not be construed as, endorsement, recommendation, or promotion of any product, service, or organization.

In this podcast, we shine a light on blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and highly aggressive hematologic malignancy.

Before 2018, there were no approved treatments for BPDCN, and oncologists typically used chemotherapy regimens commonly used for acute leukemias and lymphomas that were associated with limited durability and high rates of induction mortality.

The landscape changed when the FDA approved tagraxofusp, a CD123-directed fusion protein, as the first therapy approved for adult and pediatric patients 2 years and older with BPDCN.

Listen to Thomas LeBlanc explore the safety and efficacy of tagraxofusp from STML-401-0114 and real-world evidence, as well as how he approaches optimizing clinical management and interdisciplinary care.

Topics covered:

• How BPDCN presents and what steps are needed to make a correct diagnosis
• The safety and efficacy outcomes from STML-401-0114, including patient subgroups based on patients' age, fitness, or baseline skin burden
• How real-world evidence complements the findings from the pivotal STML-401-0114 study
• How the 'Prepare, Look, Apply, and Next Steps' (PLAN) management framework can help your team monitor and manage adverse events

Speaker:

Thomas LeBlanc

1. Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, North Carolina, USA

INDICATION

• Tagraoxfusp is a CD123-directed cytotoxin indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older

IMPORTANT SAFETY INFORMATION

Boxed WARNING: CAPILLARY LEAK SYNDROME

• Capillary Leak Syndrome (CLS), which may be life-threatening or fatal, can occur in patients receiving tagraxofusp. Monitor for signs and symptoms of CLS and take actions as recommended.

WARNINGS AND PRECAUTIONS

Capillary Leak Syndrome

• Capillary leak syndrome (CLS), including life-threatening and fatal cases, has been reported among patients treated with tagraxofusp. In patients receiving tagraxofusp in clinical trials, the overall incidence of CLS was 53% (65/122), including Grade 1 or 2 in 43% (52/122) of patients, Grade 3 in 7% (8/122) of patients, Grade 4 in 1% (1/122) of patients, and four fatalities (3%). The median time to onset was 4 days (range-1 to 46 days), and all but 5 patients experienced an event in Cycle 1.
• Before initiating therapy with tagraxofusp, ensure that the patient has adequate cardiac function and serum albumin is greater than or equal to 3.2 g/dL. During treatment with tagraxofusp, monitor serum albumin levels prior to the initiation of each dose of tagraxofusp and as indicated clinically thereafter, and assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema, including pulmonary edema, hypotension or hemodynamic instability.

Hypersensitivity Reactions

• Tagraxofusp can cause severe hypersensitivity reactions. In patients receiving tagraxofusp in clinical trials, hypersensitivity reactions were reported in 43% (53/122) of patients treated with tagraxofusp and were Grade ≥ 3 in 7% (9/122). Manifestations of hypersensitivity reported in ≥ 5% of patients include rash, pruritus, and stomatitis. Monitor patients for hypersensitivity reactions during treatment with tagraxofusp. Interrupt tagraxofusp infusion and provide supportive care as needed if a hypersensitivity reaction should occur.

Hepatotoxicity

• Treatment with tagraxofusp was associated with elevations in liver enzymes. In patients receiving tagraxofusp in clinical trials, elevations in ALT occurred in 79% (96/122) and elevations in AST occurred in 76% (93/122). Grade 3 ALT elevations were reported in 26% (32/122) of patients. Grade 3 AST elevations were reported in 30% (36/122) and Grade 4 AST elevations were reported in 3% (4/122) of patients. Elevated liver enzymes occurred in the majority of patients in Cycle 1 and were reversible following dose interruption.
• Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to each infusion with tagraxofusp. Withhold tagraxofusp temporarily if the transaminases rise to greater than 5 times the upper limit of normal and resume treatment upon normalization or when resolved.

ADVERSE REACTIONS:

Most common adverse reactions (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, pyrexia, peripheral edema, and weight increase. Most common laboratory abnormalities (incidence ≥ 50%) are decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST.

Please see Full Prescribing Information, including Boxed WARNING.

To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

MED-05440 / © 2026 Stemline Therapeutics, Inc. All rights reserved. 07/2026

In the final episode of this series, Angela Frazer-Wicks MBE reflects on her journey from trauma and loss to advocacy and system change. She discusses the value of peer support, the importance of incorporating lived experience into service design, and the progress made in understanding maternal vulnerability. This episode offers practical insights into building more compassionate, preventative, and trauma-informed systems for women and families.

Timestamps:

00:00–00:42: Intro

00:43–05:06: New beginnings

05:07–09:49: Lived experiences

09:50–14:49: Peer support

14:50–19:49: Care reforms

19:50–20:16: Outro

What are the health impacts of child removal and family separation? In Part 2 of this series, Angela Frazer-Wicks MBE discusses the often overlooked psychological and emotional consequences of child removal and family separation. She shares insights into grief, stigma, shame, and the long-term impact these experiences can have on maternal wellbeing. This episode explores gaps in support services and highlights the crucial role healthcare professionals can play in helping mothers navigate loss and recovery.

Timestamps:

00:00–00:44: Intro

00:45–06:42: Unresolved grief

06:43–09:54: Overcoming shame

09:55–11:19: Mental support

11:20–13:56: HCP advocacy

13:57–17:07: Building trust

17:08–17:26: Outro

In this episode of Onc Now, Miguel Reis Ferreira explores the evolving relationship between the microbiome and cancer, from treatment-related toxicity and tumour-associated bacteria to the potential of AI and microbiome-based biomarkers in precision oncology.

Timestamps:

00:00 – Introduction

01:28 – Clinical and Research Interests

06:52 – Microbiome and Treatment Toxicity

10:12 – Personalising Radiotherapy with Biomarkers

12:40 – Bacteria Within Tumours

18:02 – The Future of Oncomicrobiology

19:17 – AI in Radiation Oncology

21:48 – Unanswered Questions in Microbiome Research

23:35 – Three Wishes for Oncology

Angela Frazer-Wicks MBE joins host Saranya Ravindran to explore the complex relationship between trauma, domestic abuse, maternal mental health, and safeguarding. Drawing on her lived experience, Angela discusses the impact of coercive control, barriers to accessing support, and opportunities for earlier intervention by healthcare professionals. This episode examines how clinicians can better recognise vulnerability and provide trauma-informed care before families reach crisis point.

Timestamps:

00:00–00:47: Intro

00:47–04:08: Angela's story

04:09–06:10: Childhood trauma

06:11–09:34: Systemic failures

09:34–12:55: Coercive control

12:55–13:14: Outro

In this rapid-fire episode, Angela Frazer-Wicks MBE shares powerful insights from her lived experience of maternal mental health challenges, domestic abuse, and family separation. From common misconceptions about vulnerable mothers to the support every woman in crisis should have access to, this concise episode offers valuable perspectives for healthcare professionals seeking to better understand and support women facing adversity. Perfect for listeners short on time but looking to gain meaningful insights in just a few minutes.